| Ytd | 35.46% | |
| 1y | 170.39% |
| Open | 41.86 | Prev Close | 42.56 | Low | 41.04 | High | 43.00 | Mkt Cap | 1.55B |
| Vol | 77.04K | Avg Vol | 367.71K | EPS | -2.60 | P/E | -16.37 | Forward P/E | -9.56 |
| Beta | 0.94 | Short Ratio | 7.43 | Inst. Own | 109.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 38.55 | 200-d Avg | 31.54 | 1yr Est | 56.64 |
RAPP News
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rat
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains
COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on
Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wi
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“R
Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seiz
MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CR
This Boston-based biotech innovator in CNS disorders just reported significant insider selling amid
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90%
A Paris, le 8 avril 2026 COMMUNIQUE INFORMATION REGLEMENTEE Communiqué précisant les modalités de mi
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rec
LONDON--(BUSINESS WIRE)--Neuphonic and Rapport (a division of Speech Graphics) today announced a par
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (
Ci-joint le rapport financier annuel 2025 Attachment Rapport Financier CRCAM 2025
Rapport Therapeutics, Inc. (RAPP) might move higher on growing optimism about its earnings prospects
Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript
Capital International Investors grew its position in shares of Rapport Therapeutics, Inc. (NASDAQ: R
Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025
RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seiz
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,
